JP2007518741A - 1以上の薬剤を含む液体サプリメント組成物 - Google Patents
1以上の薬剤を含む液体サプリメント組成物 Download PDFInfo
- Publication number
- JP2007518741A JP2007518741A JP2006549705A JP2006549705A JP2007518741A JP 2007518741 A JP2007518741 A JP 2007518741A JP 2006549705 A JP2006549705 A JP 2006549705A JP 2006549705 A JP2006549705 A JP 2006549705A JP 2007518741 A JP2007518741 A JP 2007518741A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- present
- liquid composition
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 124
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 229940079593 drug Drugs 0.000 title claims abstract description 48
- 239000007788 liquid Substances 0.000 title claims abstract description 42
- 239000013589 supplement Substances 0.000 title description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000796 flavoring agent Substances 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 16
- 235000019634 flavors Nutrition 0.000 claims description 10
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 8
- 240000003768 Solanum lycopersicum Species 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 239000005912 Lufenuron Substances 0.000 claims description 6
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 claims description 6
- 229960000521 lufenuron Drugs 0.000 claims description 6
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 5
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 5
- 229960002418 ivermectin Drugs 0.000 claims description 5
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 claims description 5
- 229940099245 milbemycin oxime Drugs 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 4
- 229960004816 moxidectin Drugs 0.000 claims description 3
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 3
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 claims description 3
- 229960002245 selamectin Drugs 0.000 claims description 3
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- CFRPSFYHXJZSBI-DHZHZOJOSA-N (E)-nitenpyram Chemical compound [O-][N+](=O)/C=C(\NC)N(CC)CC1=CC=C(Cl)N=C1 CFRPSFYHXJZSBI-DHZHZOJOSA-N 0.000 claims description 2
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 239000005899 Fipronil Substances 0.000 claims description 2
- 239000005906 Imidacloprid Substances 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 229940013764 fipronil Drugs 0.000 claims description 2
- YWTYJOPNNQFBPC-UHFFFAOYSA-N imidacloprid Chemical compound [O-][N+](=O)\N=C1/NCCN1CC1=CC=C(Cl)N=C1 YWTYJOPNNQFBPC-UHFFFAOYSA-N 0.000 claims description 2
- 229940056881 imidacloprid Drugs 0.000 claims description 2
- 229940079888 nitenpyram Drugs 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 description 24
- 238000011282 treatment Methods 0.000 description 12
- 235000013372 meat Nutrition 0.000 description 9
- 235000016068 Berberis vulgaris Nutrition 0.000 description 8
- 241000335053 Beta vulgaris Species 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 235000013882 gravy Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 7
- 238000001125 extrusion Methods 0.000 description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 7
- 229940012843 omega-3 fatty acid Drugs 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- -1 for example Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 241000244206 Nematoda Species 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000015067 sauces Nutrition 0.000 description 5
- 241000238876 Acari Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 244000000013 helminth Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000006014 omega-3 oil Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000824799 Canis lupus dingo Species 0.000 description 3
- 241000242722 Cestoda Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 244000078703 ectoparasite Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 244000079386 endoparasite Species 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 201000006353 Filariasis Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 241000258242 Siphonaptera Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000010491 tara gum Nutrition 0.000 description 2
- 239000000213 tara gum Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- VQWNGCSUNKJFLW-AULPGBDISA-N (12e)-16-ethyl-6,8,9-trihydroxy-12-(methoxymethyl)-25,27-dimethyl-2-propyl-1-oxa-4-azacyclooctacosa-12,14-diene-3,20,28-trione Chemical compound CCCC1OC(=O)C(C)CC(C)CCCCC(=O)CCCC(CC)C=C\C=C(COC)/CCC(O)C(O)CC(O)CNC1=O VQWNGCSUNKJFLW-AULPGBDISA-N 0.000 description 1
- PQVQBAAWCOTEBG-NSVWQLETSA-N (2s)-2-amino-n-[(3r,4r,4ar,5r,6r)-5,6,8-trihydroxy-3-methyl-1-oxo-3,4,4a,5,6,7-hexahydroisochromen-4-yl]propanamide Chemical compound C1[C@@H](O)[C@H](O)[C@H]2[C@@H](NC(=O)[C@@H](N)C)[C@@H](C)OC(=O)C2=C1O PQVQBAAWCOTEBG-NSVWQLETSA-N 0.000 description 1
- QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RWMSXNCJNSILON-UHFFFAOYSA-N 2-[4-(2-propylpentyl)piperidin-1-yl]ethanol Chemical compound CCCC(CCC)CC1CCN(CCO)CC1 RWMSXNCJNSILON-UHFFFAOYSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- PQVQBAAWCOTEBG-UHFFFAOYSA-N Actinobolin Natural products C1C(O)C(O)C2C(NC(=O)C(N)C)C(C)OC(=O)C2=C1O PQVQBAAWCOTEBG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006004 Flea Infestations Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 229930189983 Myxovirescin Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 206010037651 Pyometra Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000003503 anal sac Anatomy 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229940029995 appetite stimulants Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- PNKZWORAKUEYKU-UHFFFAOYSA-N n-morpholin-4-ylhydroxylamine Chemical class ONN1CCOCC1 PNKZWORAKUEYKU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 229950002404 octapinol Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000002765 pyometritis Diseases 0.000 description 1
- 229960000996 pyrantel pamoate Drugs 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 201000001064 tick infestation Diseases 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Abstract
Description
本明細書の組成物は、コンパニオンアニマルによる使用に適合されている。この点で、当業者にはよく理解されるように、本明細書に記載の組成物の主な用途は、コンパニオンアニマル用であり、したがって、組成物は、そのように配合される。
(a)薬剤;
(b)風味剤;
(c)水;及び、
前記組成物は糖類を本質的に含まず、該組成物はコンパニオンアニマルによる使用に適合されている。本明細書において提供される本発明の液体組成物は、比較的低い糖含有量を有する。例えば、糖類は、過体重若しくは高齢の動物、又は前糖尿病若しくは糖尿病疾患になりやすい動物など、種々のコンパニオンアニマルの健康にとって有害である可能性がある。本明細書で使用する時、用語「糖類」は、集合的に、例えば、グルコース、スクロース、フルクトース、高フルクトースコーンシロップ、ラクトース、マルトース及び他の甘味剤などの単糖類及び二糖類をいう。それに関して、本明細書で使用する時、用語「糖類を本質的に含まない」とは、本発明の目的のために、本明細書における液体組成物がその組成物の約10重量%未満の糖類、或いは約5重量%未満の糖類、或いは約2重量%未満の糖類、或いは約1重量%未満の糖類、或いは約0.5重量%未満の糖類しか含まないということを意味する。本明細書において定義されるように、所与の組成物中に存在する糖類の総量は、いかなる添加された糖類、並びに組成物の任意の構成成分中に天然に存在するいかなる糖類をも含む。
本明細書の組成物は、1以上の薬剤を含む。薬剤は当業者には周知であり、選択される薬剤は、本明細書の教義に従って治療されるコンパニオンアニマルの必要性に基づく。本明細書の薬剤は、病気若しくは他の疾患の症状を治療、予防又は軽減するために動物の直接管理において使用される薬物、その構成成分、又は他の組成物である。本発明に従って治療されることができる疾患には、ノミ、ダニ、蚊、幼虫、犬糸状虫、鉤虫、線虫、鞭虫、パルボウイルス、及び他の寄生生物を含む、外部寄生虫及び内部寄生虫(endoprarasites)全般に関連するものが挙げられるが、これらに限定されない。これは単に例示を目的としており、当業者は所望の治療に必要な薬剤を選択できるであろう。
いかなる種々の動物肉、ブロス、又は脂肪も、本組成物の構成成分として使用してよい。例えば、鶏、豚、牛、子牛、魚などの動物肉を使用してよい。このような肉は、組成物が全体として液体の形態を維持するように、噴霧乾燥された動物肉のような粒子又は塊の形態であるのが有利である。いかなる動物肉のブロス及び脂肪も使用してよい。加えて、人工の、又は他の天然の風味剤を、本発明の組成物の美味性を増進させるために使用してよい。
液体組成物は、その組成物の少なくとも約50重量%の水をさらに含む。組成物は典型的には、通常の栄養必要物に対するサプリメントとしてコンパニオンアニマルによって使用されるように意図されている。このように、これらの組成物は飲料水、グレービー、又は他のサプリメントとして提供されるのが有利である。飲料水は、そのコンパニオンアニマルに与えられる通常の飲料水と完全に若しくは部分的に置き換えられてよく、又はコンパニオンアニマル用食品と接触させ若しくは混合してもよい。本明細書で記載する時、グレービーは広義に定義される。グレービーは、いかなるグレービー、トッピング、ソース、又は他の液体混合物であってもよい。グレービーは周囲温度で蒸留水よりも高い粘度を有していてよい。グレービーは、コンパニオンアニマルに直接経口投与されてもよいが、経口投与する前に食品と接触させ又は混合するのが有利である。
本明細書の組成物は、例えば、特定の疾患を治療する場合のそれらの性能、所望の栄養特性、及び/又は感覚刺激特性を高めるために、追加の任意成分を含んでいてもよい。このような任意成分は、本組成物中に分散、可溶化、又は他の態様で混合されてよい。本明細書に用いるのに好適な任意成分の非限定的な例を以下に挙げる。
本明細書中のサプリメントは、所望により、しかし好ましくは、1つ以上の栄養素、特に1つ以上のビタミン類及び/又はミネラル類でさらに補強されてもよい。こうしたビタミン類及びミネラル類の非限定例としては、ナイアシン、チアミン、リボフラビン、葉酸、パントテン酸、ビオチン、ビタミンA(ビタミンA(レチノール)、β−カロチン、パルミチン酸レチノール、又は酢酸レチノールを含む)、ビタミンC、ビタミンB2、ビタミンB3、ビタミンB6、ビタミンB12、ビタミンD、ビタミンE、ビタミンK、鉄、亜鉛、銅、リン、カリウム、ヨウ素、クロム、モリブデン、フッ化物、カルシウム、マンガン、マグネシウム、又はホウ素が挙げられる。本発明のサプリメント中で安定に維持されることができ、ペットに健康上の利益を与えるために一般に当該技術分野において既知の他の治療薬としては、次のものが挙げられるが、これらに限定されない:消化の健康を改善するためのフラクトオリゴ糖(FOS);ルテイン、消化の健康を改善するためのプロバイオティクス菌;関節及び骨の健康のためのグルコサミン、並びに体重減少の促進のためのクロム。
所望により本発明に混合されてよい酸化防止剤の例としては、α−トコフェロール、アルキル没食子酸塩誘導体、ノルジヒドログアヤレト酸、アスコルビン酸、クエン酸、メタ重硫酸ナトリウム(sodium metabisuphate)、及び亜硫酸ナトリウムが挙げられる。ブチル化ヒドロキシアニソール及びブチル化ヒドロキシトルエンもまた本発明において酸化防止剤として使用してもよい。
1以上のω−3−脂肪酸を本サプリメントに添加してもよい。本明細書において所望により使用されるω−3−脂肪酸は、いかなるω−3−脂肪酸又はω−3−脂肪酸の組み合わせであってもよい。本明細書で使用するのに好適なω−3−脂肪酸の非限定例としては、エイコサペンタエン酸(EPAとしても既知)、ドコサヘキサエン酸(DHAとしても既知)、及びこれらの混合物が挙げられる。ω−3−脂肪酸はしばしば、メンハーデン(ニシンに似た魚)を含む海産(魚)供給源、又は亜麻などの他の供給源から誘導される。
さらに1以上の防腐剤を本明細書において使用してもよい。好ましい防腐剤としては、例えば、ソルベート、ベンゾエート、及びポリホスフェート防腐剤が挙げられる。pHが約3.5未満のレベルに操作される場合、防腐剤は任意に回避されてもよい。
1以上の乳化剤及び/又は油もまた、歯ごたえ及び不透明性の目的のために本サプリメント組成物に含まれてよい。本明細書で有用な典型的な乳化剤及び油としては、例えば、モノ−ジグリセリド類、レシチン、パルプ、綿実油、及び植物油が挙げられる。
粘稠な混合物又は組成物を生成するために1以上の懸濁剤を本サプリメント組成物中で使用してもよい。通常使用される懸濁剤としては、タラガム、ジェランガム、グアーガム、キサンタンガム、アラビアゴム、ガティゴム、トラガカントガム、イナゴマメゴム、カルボキシメチルセルロース、アルギネートなどが挙げられる。特に好ましいガムとしては、キサンタンガム、タラガム、及びグアーガムが挙げられる。
本発明の方法は、コンパニオンアニマルにおける疾患を治療するために本発明の組成物をコンパニオンアニマルに経口投与(即ち摂食を通して)することを含む。本明細書の一実施形態では、組成物中の薬剤の投与は、次の疾患の任意の1つ以上の治療をもたらし得る:ノミ、ダニ、蚊、幼虫、犬糸状虫、鉤虫、線虫、鞭虫及び他の寄生生物を含む外部寄生虫並びに内部寄生虫全般。
本明細書で記載した組成物は、当業者に周知の方法に従って製造される。本発明はコンパニオンアニマルに薬剤を投与する方法を提供する。例えば、本発明の組成物は、すべての成分が可溶化されるか又は十分に分散されるまで機械的攪拌器で攪拌して、すべての構成成分を、単独で又は好適な組み合わせにより一緒に、また適切な場合には水中で、溶解する、分散する、ないしは別の方法で混合することにより調製されてもよい。組成物を製造するための具体的な方法は次の工程を伴う:
1.槽に水を加える。
2.鶏脂肪に酸化防止剤を加え、よく混合する。
3.絶え間なく攪拌しながら、液体FOS及び鶏脂肪を水に加える。完全に混合する。
4.固形の肉粉末、ブロス粉末、キサンタンガム、ビタミン類とミネラル類とのプレミックス、及び酵母をプレミックスし、「肉プレミックス」を形成する。
5.絶え間なく攪拌しながら、肉プレミックスをゆっくり加えてよく混合し、粉末が確実によく分散されるようにする。(或いは、キサンタンガムは、そのガムの十分な分散を確実にするため、周知の高剪断技術を用いて加えることができる。他の固形物もまた、絶え間なく混合しながら個々に加えることができる。)
6.生成物のバッチを粉砕機又は他の高剪断分散装置に通し、すべての粉末(特にガム)が確実によく分散されて粉末の大きな塊が残らないようにする。
7.ビートパルプ、亜麻及び野菜を含む野菜成分をプレミックスし、「野菜プレミックス」とする。
8.絶え間なく攪拌しながら、野菜プレミックスをバッチにゆっくりと加える。よく混合する。
9.バッチを91℃(195°F)まで加熱し、5分間保持する。
10.バッチを少なくとも54℃(130°F)まで冷却する。
11.予測濃度のリン酸の1/2を加え、よく混合する。
12.ソルビン酸カリウムを加え、よく混合する。
13.風味料を加え、混合する。
14.さらなるリン酸を加えて目標のpHを達成する。よく混合する。
Claims (10)
- 薬剤;
風味剤;及び
水
によって特徴付けられる液体組成物であって、該組成物が糖類を本質的に含まず、コンパニオンアニマルによる使用に適合されたものである、液体組成物。 - 薬剤;
風味剤;及び
水
によって特徴付けられる液体組成物であって、該組成物がトマト風味を本質的に含まず、コンパニオンアニマルによる使用に適合されたものである、液体組成物。 - 組成物の少なくとも約50重量%の水を含む、請求項1又は請求項2に記載の液体組成物。
- 組成物の約0.00001重量%〜約99重量%の薬剤を含む、請求項1〜3のいずれか一項に記載の液体組成物。
- 約3〜約7のpHを有する、請求項1〜4のいずれか一項に記載の液体組成物。
- 前記薬剤が、イミダクロプリド、ニテンピラム、ルフェヌロン、フィプロニル、ミルベマイシン オキシム、モキシデクチン、イベルメクチン、ピランテル、ミルベマイシン オキシム、ルフェヌロン、セラメクチン及びこれらの組み合わせからなる群から選択されるものである、請求項1〜5のいずれか一項に記載の液体組成物。
- 請求項1〜6のいずれか一項に記載の組成物をコンパニオンアニマルに経口投与することを含む、前記コンパニオンアニマルにおける疾患を治療する方法。
- 前記疾患が、ノミ疾患、ダニ疾患、犬糸状虫疾患、細菌疾患、ウイルス疾患及びこれらの組み合わせからなる群から選択される、請求項7に記載の方法。
- 前記液体組成物が毎日投与される、請求項7又は請求項8に記載の方法。
- 前記液体組成物がペットフードと共に投与される、請求項7〜9のいずれか一項に記載の疾患を治療する方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/758,997 US20050158367A1 (en) | 2004-01-16 | 2004-01-16 | Liquid compositions comprising one or more medicaments |
PCT/US2005/001899 WO2005072536A1 (en) | 2004-01-16 | 2005-01-14 | Liquid supplement compositions comprising one or more medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007518741A true JP2007518741A (ja) | 2007-07-12 |
Family
ID=34749621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006549705A Pending JP2007518741A (ja) | 2004-01-16 | 2005-01-14 | 1以上の薬剤を含む液体サプリメント組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050158367A1 (ja) |
EP (1) | EP1722640A1 (ja) |
JP (1) | JP2007518741A (ja) |
CN (1) | CN1909795A (ja) |
AR (1) | AR047861A1 (ja) |
AU (1) | AU2005208775B2 (ja) |
BR (1) | BRPI0506888A (ja) |
CA (1) | CA2551833A1 (ja) |
MX (1) | MXPA06007789A (ja) |
WO (1) | WO2005072536A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011524165A (ja) * | 2008-06-03 | 2011-09-01 | ネステク ソシエテ アノニム | 嗜好性向上剤及び嗜好性を向上させる方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0601078B1 (pt) * | 2006-03-24 | 2015-10-06 | Champion Farmoquímico Ltda | Uso de Diflubenzuron |
US20100316732A1 (en) * | 2008-02-12 | 2010-12-16 | Todd James Smith | Beverage compositions for the promotion of joint health in companion animals |
US9820977B2 (en) | 2008-10-03 | 2017-11-21 | Bayer Healthcare Llc | Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent |
US20140235688A1 (en) * | 2008-10-03 | 2014-08-21 | Piedmont Pharmaceuticals, Llc. | Treatment of external parasites by oral administration of parasiticidal agents |
US20100127019A1 (en) * | 2008-11-25 | 2010-05-27 | Joseph Wayman | Flavored Supplements in Liquid Form to be Added to Food and Methods of Using Same |
CA2811926A1 (en) | 2010-10-20 | 2012-04-26 | Galderma S.A. | Method of treating otitis externa using macrocyclic lactone compound |
BR112013015487B1 (pt) | 2011-01-14 | 2020-04-22 | Mars, Incorporated | composição alimentícia para animais de estimação compreendendo carotenóides |
GB2527555B (en) | 2014-06-25 | 2018-09-19 | Norbrook Lab Ltd | Stable methimazole liquid compositions |
CN107529789A (zh) | 2015-04-28 | 2018-01-02 | 马斯公司 | 制备灭菌湿宠物食品的方法 |
AU2016255430C1 (en) * | 2015-04-28 | 2021-02-11 | Mars, Incorporated | Wet pet food product comprising a meat analogue |
CN106511267A (zh) * | 2017-01-18 | 2017-03-22 | 佛山市南海东方澳龙制药有限公司 | 复方莫昔克丁滴剂及其制备方法和应用 |
WO2024059803A1 (en) * | 2022-09-15 | 2024-03-21 | In The Bowl Animal Health, Inc. | Feed and methods for controlling intestinal tract parasitic worm infections in mammals |
US11801263B1 (en) | 2023-03-01 | 2023-10-31 | Mike Ray | Heartworm medicament |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5238377A (en) * | 1975-09-11 | 1977-03-24 | Hoechst Ag | Usage and growth improving agent for ruminants |
JPH0435575A (ja) * | 1990-05-31 | 1992-02-06 | Sharp Corp | Muse信号の同期分離回路 |
JPH0767544A (ja) * | 1993-09-03 | 1995-03-14 | Taiyo Kagaku Co Ltd | 飼料組成物及び飼料 |
JPH08131085A (ja) * | 1994-03-28 | 1996-05-28 | Iams Co:The | 発酵性繊維を含むペット動物用飼料及び胃腸障害の治療方法 |
JP2002522310A (ja) * | 1998-08-12 | 2002-07-23 | クロッケ フェアパックングス−ゼルヴィース ゲーエムベーハー | 多室容器 |
WO2003030653A2 (en) * | 2001-10-05 | 2003-04-17 | Rubicon Scientific Llc | Animal feeds including actives and methods of using same |
JP2003112782A (ja) * | 2001-09-19 | 2003-04-18 | Kemikosu Creations Kk | 2種の物質の分離貯蔵・混合容器 |
WO2003086097A1 (en) * | 2002-04-08 | 2003-10-23 | Peros Systèmes Technologies Inc. | Composition for modulating a physiological reaction or inducing an immune response |
JP2003531873A (ja) * | 2000-05-03 | 2003-10-28 | ドシルバ,ジヨー | 液体投与調合物を製造する方法および装置 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4702914A (en) * | 1984-04-30 | 1987-10-27 | Ryan Hillary A | Veterinary-sauce prophylactic |
GB8907313D0 (en) * | 1989-03-31 | 1989-05-17 | British Sugar Plc | Sweetener composition |
EP0945131A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Perorale Wirkstoff-Suspension |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
US5932258A (en) * | 1998-04-06 | 1999-08-03 | The Iams Company | Composition and process for improving glucose metabolism in companion animals |
JP2002527362A (ja) * | 1998-10-09 | 2002-08-27 | ノバルテイス・アクチエンゲゼルシヤフト | ノミに対するルフェヌロンおよびニテンピラムの経口用配合物 |
JP2001226293A (ja) * | 2000-02-17 | 2001-08-21 | Kotaro Kanpo Seiyaku Kk | 服用補助剤 |
EP1136067A1 (en) * | 2000-03-23 | 2001-09-26 | Pfizer Limited | Oral formulations of medicaments |
MY128159A (en) * | 2000-06-30 | 2007-01-31 | Wyeth Corp | Methods and composition for oral vaccination |
US20030194423A1 (en) * | 2002-04-15 | 2003-10-16 | Mars, Inc. | Composition for enhancing nutritional content of food |
-
2004
- 2004-01-16 US US10/758,997 patent/US20050158367A1/en not_active Abandoned
-
2005
- 2005-01-14 CA CA002551833A patent/CA2551833A1/en not_active Abandoned
- 2005-01-14 CN CNA2005800023801A patent/CN1909795A/zh active Pending
- 2005-01-14 WO PCT/US2005/001899 patent/WO2005072536A1/en not_active Application Discontinuation
- 2005-01-14 JP JP2006549705A patent/JP2007518741A/ja active Pending
- 2005-01-14 EP EP05705979A patent/EP1722640A1/en not_active Withdrawn
- 2005-01-14 MX MXPA06007789A patent/MXPA06007789A/es not_active Application Discontinuation
- 2005-01-14 BR BRPI0506888-6A patent/BRPI0506888A/pt not_active IP Right Cessation
- 2005-01-14 AR ARP050100157A patent/AR047861A1/es unknown
- 2005-01-14 AU AU2005208775A patent/AU2005208775B2/en not_active Ceased
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5238377A (en) * | 1975-09-11 | 1977-03-24 | Hoechst Ag | Usage and growth improving agent for ruminants |
JPH0435575A (ja) * | 1990-05-31 | 1992-02-06 | Sharp Corp | Muse信号の同期分離回路 |
JPH0767544A (ja) * | 1993-09-03 | 1995-03-14 | Taiyo Kagaku Co Ltd | 飼料組成物及び飼料 |
JPH08131085A (ja) * | 1994-03-28 | 1996-05-28 | Iams Co:The | 発酵性繊維を含むペット動物用飼料及び胃腸障害の治療方法 |
JP2002522310A (ja) * | 1998-08-12 | 2002-07-23 | クロッケ フェアパックングス−ゼルヴィース ゲーエムベーハー | 多室容器 |
JP2003531873A (ja) * | 2000-05-03 | 2003-10-28 | ドシルバ,ジヨー | 液体投与調合物を製造する方法および装置 |
JP2003112782A (ja) * | 2001-09-19 | 2003-04-18 | Kemikosu Creations Kk | 2種の物質の分離貯蔵・混合容器 |
WO2003030653A2 (en) * | 2001-10-05 | 2003-04-17 | Rubicon Scientific Llc | Animal feeds including actives and methods of using same |
WO2003086097A1 (en) * | 2002-04-08 | 2003-10-23 | Peros Systèmes Technologies Inc. | Composition for modulating a physiological reaction or inducing an immune response |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011524165A (ja) * | 2008-06-03 | 2011-09-01 | ネステク ソシエテ アノニム | 嗜好性向上剤及び嗜好性を向上させる方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2551833A1 (en) | 2005-08-11 |
AU2005208775A1 (en) | 2005-08-11 |
AU2005208775B2 (en) | 2009-01-08 |
MXPA06007789A (es) | 2007-04-20 |
EP1722640A1 (en) | 2006-11-22 |
BRPI0506888A (pt) | 2007-06-12 |
CN1909795A (zh) | 2007-02-07 |
WO2005072536A1 (en) | 2005-08-11 |
AR047861A1 (es) | 2006-03-01 |
US20050158367A1 (en) | 2005-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007518741A (ja) | 1以上の薬剤を含む液体サプリメント組成物 | |
US6506413B1 (en) | Compositions for treating animal diseases and syndromes | |
AU2006320167C1 (en) | Methods for altering stool quality and/or stool frequency | |
US20090324761A1 (en) | Methods And Compositions for Improving Gastrointestinal Health | |
JP5191955B2 (ja) | 粘膜免疫調節剤並びにその用途 | |
WO2004112776A2 (en) | Inflammatory disease treatment | |
JP2009500337A (ja) | 炎症性疾患を予防または治療するための方法および組成物 | |
ZA200603603B (en) | Fluid composition for increased total water intake | |
MXPA05012050A (es) | Complemento dietetico y metodo para el tratamiento y prevencion de ulceras del tracto digestivo en equinos y otros animales. | |
ZA200508645B (en) | Oral administration form for veterinary use | |
US8197842B2 (en) | Dietary supplement and method | |
CN102600304A (zh) | 一种用于畜禽支原体肺炎治疗的纳米乳组合物及其制备方法 | |
US8778385B1 (en) | Medicated animal food composition | |
US20200330416A1 (en) | Method and composition for improved hydration in animals | |
US10426840B2 (en) | Oil suspension of metronidazole | |
US20090208588A1 (en) | GERD carbohydrate compositions | |
JP2014504288A (ja) | 改良された鉱物系組成物および使用方法 | |
CA2718966A1 (en) | Anti-inflammatory drug delivery system | |
JP2022030024A (ja) | ゲル誘導型のペット投薬補助用組成物 | |
US20150150932A1 (en) | Soluable fiber digestive therapy and delivery system | |
WO2022198329A1 (en) | Water-based iron supplement formulations for dosing animal neonates | |
JP2021193979A (ja) | 家畜の初乳品質改善剤及び方法 | |
Lohmann | Management and care of the geriatric horse. | |
Pascoe et al. | Ulcer update: a top researcher explains why stomach ulcers are common in horses--and what you can do about them | |
Thompson | WVC 2017: Mirtazapine for Appetite Stimulation in Cats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100318 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100326 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100416 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100915 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100924 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101015 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101022 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101115 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110304 |